In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, Lyubomir T., Vu, Binh T., Graves, Bradford, Carvajal, Daisy, Podlaski, Frank, Filipovic, Zoran, Kong, Norman, Kammlott, Ursula +4 more·2004·Science
DOI 10.1126/science.1092472

Cited by (1,103)

Items 101–200 of 1,103

  1. Tumour suppression by p53: a role for the DNA damage response?
    David W. Meek · 2009 · Nature reviews. Cancer
  2. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions
    Helge Siemens, René Jackstadt, Sabine Hünten, Markus Kaller, Antje Menssen, Ursula Götz, Heiko Hermeking · 2011 · Cell Cycle
  3. Inactivation of the p53 pathway in retinoblastoma
    Laurie, Nikia A., Donovan, Stacy L., Shih, Chie-Schin, Zhang, Jiakun, Mills, Nicholas, Fuller, Christine, Teunisse, Amina, Lam, Suzanne, Ramos, Yolande, Mohan, Adithi et al. · 2006 · Nature
  4. Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
    Ding, Qingjie, Zhang, Zhuming, Liu, Jin-Jun, Jiang, Nan, Zhang, Jing, Ross, Tina M., Chu, Xin-Jie, Bartkovitz, David, Podlaski, Frank, Janson, Cheryl et al. · 2013 · Journal of Medicinal Chemistry
  5. The role of p53 in cancer drug resistance and targeted chemotherapy
    Karin Hientz, André Mohr, Dipita Bhakta-Guha, Thomas Efferth · 2016 · Oncotarget
  6. Pharmacological inhibitors of glycogen synthase kinase 3
    Laurent Meijer, Marc Flajolet, Paul Greengard · 2004 · Trends in Pharmacological Sciences
  7. Transcriptional Regulation by P53
    Beckerman, R., Prives, C. · 2010 · Cold Spring Harbor Perspectives in Biology
  8. Signaling to p53: ribosomal proteins find their way
    Zhang, Yanping, Lu, Hua · 2009 · Cancer Cell
  9. The Molecular Basis for the Pharmacokinetics and Pharmacodynamics of Curcumin and Its Metabolites in Relation to Cancer
    Michal Heger, Rowan F. van Golen, Mans Broekgaarden, Martin Christian Michel · 2013 · Pharmacological Reviews
  10. The expanding universe of p53 targets
    Menendez, Daniel, Inga, Alberto, Resnick, Michael A. · 2009 · Nature Reviews Cancer
  11. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
    Ray-Coquard, Isabelle, Blay, Jean-Yves, Italiano, Antoine, Le Cesne, Axel, Penel, Nicolas, Zhi, Jianguo, Heil, Florian, Rueger, Ruediger, Graves, Bradford, Ding, Meichun et al. · 2012 · The Lancet Oncology
  12. Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets
    Bedford, Lynn, Lowe, James, Dick, Lawrence R., Mayer, R. John, Brownell, James E. · 2011 · Nature Reviews Drug Discovery
  13. Reactivation of the p53 Tumor Suppressor Pathway by a Stapled p53 Peptide
    Federico Bernal, Andrew F. Tyler, Stanley J. Korsmeyer, Loren D. Walensky, Gregory L. Verdine · 2007 · Journal of the American Chemical Society
  14. p53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells
    Amy Tarangelo, Leslie Magtanong, Kathryn T. Bieging-Rolett, Yang Li, Jiangbin Ye, Laura Donatella Attardi, Scott J. Dixon · 2018 · Cell Reports
  15. Targeting mutant p53 for cancer therapy: direct and indirect strategies
    Jiahao Hu, Jiasheng Cao, Win Topatana, Sarun Juengpanich, Shijie Li, Bin Zhang, Jiliang Shen, Liuxin Cai, Xiujun Cai, Mingyu Chen · 2021 · Journal of Hematology & Oncology
  16. Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction
    Buckley, Dennis L., Van Molle, Inge, Gareiss, Peter C., Tae, Hyun Seop, Michel, Julien, Noblin, Devin J., Jorgensen, William L., Ciulli, Alessio, Crews, Craig M. · 2012 · Journal of the American Chemical Society
  17. ARF-BP1/Mule Is a Critical Mediator of the ARF Tumor Suppressor
    Delin Chen, Ning Kon, Muyang Li, Wenzhu Zhang, Jun Qin, Wei Jun Gu · 2005 · Cell
  18. MDM2 inhibitors for cancer therapy
    Vassilev, Lyubomir T. · 2007 · Trends in Molecular Medicine
  19. Coping with stress: multiple ways to activate p53
    Horn, H F, Vousden, K H · 2007 · Oncogene
  20. Natürliche Pyrrolidinylspirooxindole als Vorlagen für die Entwicklung medizinischer Wirkstoffe
    Chris V. Galliford, Karl A. Scheidt · 2007 · Angewandte Chemie
  21. Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator
    Sonia Laı́n, Jonathan J. Hollick, Johanna Campbell, Oliver D. Staples, Maureen Higgins, Mustapha Aoubala, Anna R. McCarthy, Virginia C. L. Appleyard, Karen E. Murray, Lee Baker et al. · 2008 · Cancer Cell
  22. Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
    Sabapathy, Kanaga, Lane, David P. · 2018 · Nature Reviews Clinical Oncology
  23. Chemotherapeutic Approaches for Targeting Cell Death Pathways
    Marco Ricci, Wei‐Xing Zong · 2006 · The Oncologist
  24. p53 regulates epithelial–mesenchymal transition through microRNAs targeting ZEB1 and ZEB2
    Tae‐Wan Kim, Angelo Veronese, Flavia Pichiorri, Tae Jin Lee, Young-Jun Jeon, Stefano Volinia, Pascal Pineau, Agnès Marchio, Jeff Palatini, Sung-Suk Suh et al. · 2011 · The Journal of Experimental Medicine
  25. Understanding the complexity of p53 in a new era of tumor suppression
    Yanqing Liu, Zhenyi Su, Omid Tavana, Wei Jun Gu · 2024 · Cancer Cell
  26. Short Linear Motifs: Ubiquitous and Functionally Diverse Protein Interaction Modules Directing Cell Regulation
    Kim Van Roey, Bora Uyar, Robert J. Weatheritt, Holger Dinkel, Markus Seiler, Aidan Budd, Toby J. Gibson, Norman E. Davey · 2014 · Chemical Reviews
  27. Survey of the year 2003 commercial optical biosensor literature
    Rebecca L. Rich, David G. Myszka · 2004 · Journal of Molecular Recognition
  28. Genetically engineered mouse models in oncology research and cancer medicine
    Kersten, Kelly, de Visser, Karin E, van Miltenburg, Martine H, Jonkers, Jos · 2017 · EMBO Molecular Medicine
  29. A decade and a half of protein intrinsic disorder: Biology still waits for physics
    V. Uversky · 2013 · Protein Science
  30. Modulators of Protein–Protein Interactions
    Milroy, Lech-Gustav, Grossmann, Tom N., Hennig, Sven, Brunsveld, Luc, Ottmann, Christian · 2014 · Chemical Reviews
  31. A G3BP1-Interacting lncRNA Promotes Ferroptosis and Apoptosis in Cancer via Nuclear Sequestration of p53
    Chao Mao, Xiang Wang, Yating Liu, Min Wang, Bin Yan, Yiqun Jiang, Ying Shi, Yi Shen, Xiaoli Liu, Weiwei Lai et al. · 2018 · Cancer Research
  32. Inhibition of SIRT1 Catalytic Activity Increases p53 Acetylation but Does Not Alter Cell Survival following DNA Damage
    Jonathan M. Solomon, Rao Pasupuleti, Lei Xu, Thomas McDonagh, Rory Curtis, Peter S. DiStefano, L. Julie Huber · 2005 · Molecular and Cellular Biology
  33. Recent applications of multicomponent reactions in medicinal chemistry
    Paul Slobbe, Eelco Ruijter, Romano V. A. Orrù · 2012 · MedChemComm
  34. Senescence-Associated Exosome Release from Human Prostate Cancer Cells
    Lehmann, Brian D., Paine, Matthew S., Brooks, Adam M., McCubrey, James A., Renegar, Randall H., Wang, Rong, Terrian, David M. · 2008 · Cancer Research
  35. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication
    Christ, Frauke, Voet, Arnout, Marchand, Arnaud, Nicolet, Stefan, Desimmie, Belete A, Marchand, Damien, Bardiot, Dorothée, Van der Veken, Nam Joo, Van Remoortel, Barbara, Strelkov, Sergei V et al. · 2010 · Nature Chemical Biology
  36. The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents
    Jiabei Zhou, Yu Kang, Lu Chen, Hua Wang, Junqing Liu, Su Zeng, Lushan Yu · 2020 · Frontiers in Pharmacology
  37. HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins
    Buckley, Dennis L., Raina, Kanak, Darricarrere, Nicole, Hines, John, Gustafson, Jeffrey L., Smith, Ian E., Miah, Afjal H., Harling, John D., Crews, Craig M. · 2015 · ACS Chemical Biology
  38. Development of targeted protein degradation therapeutics
    Chamberlain, Philip P., Hamann, Lawrence G. · 2019 · Nature Chemical Biology
  39. p53-Responsive MicroRNAs 192 and 215 Are Capable of Inducing Cell Cycle Arrest
    Christian Joerg Braun, Xin Zhang, Irina Savelyeva, Sonja Wolff, Ute Martha Moll, Troels Schepeler, Torben Falck Orntoft, Claus L. Andersen, Matthias Dobbelstein · 2008 · Cancer Research
  40. p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity
    Carmen Adriaens, Laura Standaert, Jasmine Barra, Mathilde Latil, Annelien Verfaillie, Peter Kalev, Bram Boeckx, Paul W.G. Wijnhoven, Enrico Radaelli, William Vermi et al. · 2016 · Nature Medicine
  41. Ageing, Cellular Senescence and Neurodegenerative Disease
    Kritsilis, Marios, V. Rizou, Sophia, Koutsoudaki, Paraskevi N., Evangelou, Konstantinos, Gorgoulis, Vassilis G., Papadopoulos, Dimitrios · 2018 · International Journal of Molecular Sciences
  42. Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment
    Zhao, Yujun, Aguilar, Angelo, Bernard, Denzil, Wang, Shaomeng · 2015 · Journal of Medicinal Chemistry
  43. Strategies for Targeting Protein–Protein Interactions With Synthetic Agents
    Hang Hubert Yin, Andrew D. Hamilton · 2005 · Angewandte Chemie International Edition
  44. Dissecting p53-dependent apoptosis
    Jerry E. Chipuk, Douglas R. Green · 2006 · Cell Death and Differentiation
  45. The p53 orchestra: Mdm2 and Mdmx set the tone
    Wade, Mark, Wang, Yunyuan V., Wahl, Geoffrey M. · 2010 · Trends in Cell Biology
  46. Regulating tumor suppressor genes: post-translational modifications
    Chen, Ling, Liu, Shuang, Tao, Yongguang · 2020 · Signal Transduction and Targeted Therapy
  47. E3 ubiquitin ligases: styles, structures and functions
    Yang, Quan, Zhao, Jinyao, Chen, Dan, Wang, Yang · 2021 · Molecular Biomedicine
  48. Inhibitors of Ubiquitin-Activating Enzyme (E1), a New Class of Potential Cancer Therapeutics
    Yili Yang, Jirouta Kitagaki, Ren‐Ming Dai, Yien Che Tsai, Kevin L. Lorick, Robert L. Ludwig, Shervon A. Pierre, Jane P. Jensen, Ilia V. Davydov, Pankaj Oberoi et al. · 2007 · Cancer Research
  49. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set
    Ogechi N. Ikediobi, Helen Ruth Davies, Graham R. Bignell, Sarah Edkins, Claire Stevens, Sarah O’Meara, Thomas Santarius, Tim Avis, Syd Barthorpe, Lisa Brackenbury et al. · 2006 · Molecular Cancer Therapeutics
  50. Pro-senescence therapy for cancer treatment
    Nardella, Caterina, Clohessy, John G., Alimonti, Andrea, Pandolfi, Pier Paolo · 2011 · Nature Reviews Cancer
  51. Drugging the undruggables: exploring the ubiquitin system for drug development
    Huang, Xiaodong, Dixit, Vishva M · 2016 · Cell Research
  52. Efficient Synthesis of Imidazoles from Aldehydes and 1,2-Diketones Using Microwave Irradiation
    Scott E. Wolkenberg, David D. Wisnoski, William Leister, Yi Wang, Zhijian Zhao, Craig W. Lindsley · 2004 · Organic Letters
  53. Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells
    Bruce L. Grasberger, Tianbao Lu, Carsten Schubert, Daniel J. Parks, Theodore E. Carver, Holly K. Koblish, Maxwell D. Cummings, Louis V. LaFrance, Karen L. Milkiewicz, Raul R. Calvo et al. · 2005 · Journal of Medicinal Chemistry
  54. Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer
    Guangbo Liu, Fen Pei, Fengqing Yang, Lingxiao Li, Amit Dipak Amin, Songnian Liu, J. Ross Buchan, William Cho · 2017 · International Journal of Molecular Sciences
  55. Phase-separating peptides for direct cytosolic delivery and redox-activated release of macromolecular therapeutics
    Yue Sun, Sze Yi Lau, Zhi Wei Lim, Shi Chieh Chang, Farid John Ghadessy, Anthony W. Partridge, Ali Miserez · 2022 · Nature Chemistry
  56. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents
    Massa, Stephen M., Yang, Tao, Xie, Youmei, Shi, Jian, Bilgen, Mehmet, Joyce, Jeffrey N., Nehama, Dean, Rajadas, Jayakumar, Longo, Frank M. · 2010 · Journal of Clinical Investigation
  57. RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis
    Stanley Lipkowitz, Allan M. Weissman · 2011 · Nature reviews. Cancer
  58. Ubiquitin–proteasome system (UPS) as a target for anticancer treatment
    Jin‐Young Park, Jinhong Cho, Eun Joo Song · 2020 · Archives of Pharmacal Research
  59. Targeting protein–protein interactions as an anticancer strategy
    Ivanov, Andrei A., Khuri, Fadlo R., Fu, Haian · 2013 · Trends in Pharmacological Sciences
  60. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75
    Cherepanov, Peter, Ambrosio, Andre L. B., Rahman, Shaila, Ellenberger, Tom, Engelman, Alan · 2005 · Proceedings of the National Academy of Sciences
  61. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis
    Daniela Hoeller, Christina-Maria Hecker, Ivan Đikić · 2006 · Nature reviews. Cancer
  62. Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib
    Ling Li, Lisheng Wang, Liang Li, Zhiqiang Wang, YinWei Ho, Tinisha McDonald, Tessa L. Holyoake, Wenyong Chen, Ravi Bhatia · 2012 · Cancer Cell
  63. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy
    Kensuke Kojima, Marina Y Konopleva, Ismael J. Samudio, Masato Shikami, Maria da Graça Cabreira-Hansen, Teresa J. McQueen, Vivian R. Ruvolo, Twee Tsao, Zhihong Zeng, Lyubomir T. Vassilev et al. · 2005 · Blood
  64. Asymmetric organocatalysis: an enabling technology for medicinal chemistry
    Bo Han, Xiang‐Hong He, Yanqing Liu, Gu He, Cheng Yun Peng, Jun‐Long Li · 2021 · Chemical Society Reviews
  65. p53 modifications: exquisite decorations of the powerful guardian
    Liu, Yanqing, Tavana, Omid, Gu, Wei · 2019 · Journal of Molecular Cell Biology
  66. DNA damage during S-phase mediates the proliferation-quiescence decision in the subsequent G1 via p21 expression
    Barr, Alexis R., Cooper, Samuel, Heldt, Frank S., Butera, Francesca, Stoy, Henriette, Mansfeld, Jörg, Novák, Béla, Bakal, Chris · 2017 · Nature Communications
  67. The Ubiquitin Ligase HectH9 Regulates Transcriptional Activation by Myc and Is Essential for Tumor Cell Proliferation
    Sovana Adhikary, Federica Marinoni, Andreas Hock, Esther Hulleman, Nikita Popov, R. Beier, Sandra Bernard, Micaela Quarto, Maria Cristina Capra, Stephan Goettig et al. · 2005 · Cell
  68. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones
    Tasuku Ishida, Alessio Ciulli · 2020 · SLAS DISCOVERY
  69. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect
    Zhang, Cen, Lin, Meihua, Wu, Rui, Wang, Xiaowen, Yang, Bo, Levine, Arnold J., Hu, Wenwei, Feng, Zhaohui · 2011 · Proceedings of the National Academy of Sciences
  70. Mitochondria-mediated apoptosis in mammals
    Shunbin Xiong, Tianyang Mu, Guowen Wang, Xuejun Jiang · 2014 · Protein & Cell
  71. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX
    Pazgier, Marzena, Liu, Min, Zou, Guozhang, Yuan, Weirong, Li, Changqing, Li, Chong, Li, Jing, Monbo, Juahdi, Zella, Davide, Tarasov, Sergey G. et al. · 2009 · Proceedings of the National Academy of Sciences
  72. New approaches to molecular cancer therapeutics
    Ian Collins, Paul Workman · 2006 · Nature Chemical Biology
  73. How viruses hijack cell regulation
    Norman E. Davey, Gilles Travé, Toby J. Gibson · 2010 · Trends in Biochemical Sciences
  74. Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development
    Vu, Binh, Wovkulich, Peter, Pizzolato, Giacomo, Lovey, Allen, Ding, Qingjie, Jiang, Nan, Liu, Jin-Jun, Zhao, Chunlin, Glenn, Kelli, Wen, Yang et al. · 2013 · ACS Medicinal Chemistry Letters
  75. Accelerated MDM2 auto‐degradation induced by DNA‐damage kinases is required for p53 activation
    Stommel, Jayne M, Wahl, Geoffrey M · 2004 · The EMBO Journal
  76. NUMB controls p53 tumour suppressor activity
    Colaluca, Ivan N., Tosoni, Daniela, Nuciforo, Paolo, Senic-Matuglia, Francesca, Galimberti, Viviana, Viale, Giuseppe, Pece, Salvatore, Di Fiore, Pier Paolo · 2008 · Nature
  77. Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
    Xie, Xin, Yu, Tingting, Li, Xiang, Zhang, Nan, Foster, Leonard J., Peng, Cheng, Huang, Wei, He, Gu · 2023 · Signal Transduction and Targeted Therapy
  78. Transcription-independent pro-apoptotic functions of p53
    Moll, Ute M, Wolff, Sonja, Speidel, Daniel, Deppert, Wolfgang · 2005 · Current Opinion in Cell Biology
  79. Translating p53 into the clinic
    Cheok, Chit Fang, Verma, Chandra S., Baselga, José, Lane, David P. · 2011 · Nature Reviews Clinical Oncology
  80. Uncovering the role of p53 splice variants in human malignancy: a clinical perspective
    Jean‐Christophe Bourdon, Sylvanie Surget, Marie P. Khoury · 2013 · OncoTargets and Therapy
  81. Classification of scaffold-hopping approaches
    Hongmao Sun, Gregory J. Tawa, Anders Wallqvist · 2011 · Drug Discovery Today
  82. MDM2 inhibition: an important step forward in cancer therapy
    Marina Y Konopleva, Giovanni Martinelli, Naval Guastad Daver, Cristina Papayannidis, Andrew H. Wei, Brian Higgins, Marion Ott, John O Mascarenhas, Michael Andreeff · 2020 · Leukemia
  83. Cancer Proliferation Gene Discovery Through Functional Genomics
    Michael R. Schlabach, Ji Luo, Nicole L. Solimini, Guang Hu, Qikai Xu, Mamie Z. Li, Zhenming Zhao, Agata Smogorzewska, Mathew E. Sowa, Xiaolu A. Cambronne et al. · 2008 · Science
  84. Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy
    Driehuis, Else, Kolders, Sigrid, Spelier, Sacha, Lõhmussaar, Kadi, Willems, Stefan M., Devriese, Lot A., de Bree, Remco, de Ruiter, Emma J., Korving, Jeroen, Begthel, Harry et al. · 2019 · Cancer Discovery
  85. Clinical and Molecular Spectrum of Liposarcoma
    Alex Thomas John Lee, Khin Thway, Paul H. Huang, Robin L. Jones · 2017 · Journal of Clinical Oncology
  86. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis
    Alimonti, Andrea, Nardella, Caterina, Chen, Zhenbang, Clohessy, John G., Carracedo, Arkaitz, Trotman, Lloyd C., Cheng, Ke, Varmeh, Shohreh, Kozma, Sara C., Thomas, George et al. · 2010 · Journal of Clinical Investigation
  87. Homogeneous and heterogeneous catalysts for multicomponent reactions
    María José Climent, Avelino Corma, Sara Iborra · 2011 · RSC Advances
  88. Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks
    Fischer, Martin, Grossmann, Patrick, Padi, Megha, DeCaprio, James A. · 2016 · Nucleic Acids Research
  89. Targeting the MDM2-p53 Interaction for Cancer Therapy
    Sanjeev Kumar Shangary, Shaomeng Wang · 2008 · Clinical Cancer Research
  90. p53mutations in colorectal cancer- molecular pathogenesis and pharmacological reactivation
    Xiao-Lan Li · 2015 · World Journal of Gastroenterology
  91. Results of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia
    Andreeff, Michael, Kelly, Kevin R., Yee, Karen, Assouline, Sarit, Strair, Roger, Popplewell, Leslie, Bowen, David, Martinelli, Giovanni, Drummond, Mark W., Vyas, Paresh et al. · 2016 · Clinical Cancer Research
  92. Targeting cell cycle regulation in cancer therapy
    Santiago Díaz‐Moralli, Míriam Tarrado‐Castellarnau, Aníbal Miranda, Marta Cascante · 2013 · Pharmacology & Therapeutics
  93. Mdm2-mediated ubiquitylation: p53 and beyond
    Marine, J-C, Lozano, G · 2010 · Cell Death & Differentiation
  94. The Tumor Suppressor p53: From Structures to Drug Discovery
    Andreas C. Joerger, Alan Roy Fersht · 2010 · Cold Spring Harbor Perspectives in Biology
  95. The role and regulation of MAFbx/atrogin-1 and MuRF1 in skeletal muscle atrophy
    Victoria C. Foletta, Lloyd J. White, Amy Larsen, Bertrand Léger, Aaron Paul Russell · 2011 · Pflügers Archiv - European Journal of Physiology
  96. Transcription-independent p53 apoptosis: an alternative route to death
    Daniel Speidel · 2009 · Trends in Cell Biology
  97. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy
    Karson S. Putt, Grace W Chen, Jennifer M Pearson, Joseph S Sandhorst, Martin S. Hoagland, Jung‐Taek Kwon, Soon-Kyung Hwang, Hua Jin, Mona I. Churchwell, Myung‐Haing Cho et al. · 2006 · Nature Chemical Biology
  98. Metabolic regulation by p53
    Oliver D.K. Maddocks, Karen H. Vousden · 2011 · Journal of Molecular Medicine
  99. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4
    Marine, J-C, Francoz, S, Maetens, M, Wahl, G, Toledo, F, Lozano, G · 2006 · Cell Death & Differentiation
  100. RETRACTED: hnRNP K: An HDM2 Target and Transcriptional Coactivator of p53 in Response to DNA Damage
    Moumen, Abdeladim, Masterson, Philip, O'Connor, Mark J., Jackson, Stephen P. · 2005 · Cell · Retracted